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institution, and the response to steroids.
Not every case will be diagnosed antemor-
tem, and not every pathology will respond
favorably to steroids. Thus, treatment must
take into consideration the possibility that
bridge to recovery or bridge to transplant
is conceivable. VAD support, therefore, is
an excellent tool to accomplish the goal—
particularly with a VAD that has features
such as short- or long-term support, bridge
to recovery or transplant, ambulation with
possibility for home discharge, and so
forth. In addition, a VAD that has left ven-
tricular (LV) apical cannulation allows for
optimal unloading of the LV while on sup-
port, antegrade flow pattern, and pulsatile
flow. Although extracorporeal life support
(ECLS) has been used extensively for acute
circulatory decompensation, the femoral–
femoral circulation is suboptimal in terms
of resting the LV and counterproductive
when the LV recovers and weaning is
attempted—there is conflicting flow from
the heart antegrade and femoral flow retro-
grade. Furthermore, extracorporeal mem-
brane oxygenation introduces an oxygen-
ator, which is appropriate when lung injury
is associated with the heart condition but
potentially detrimental when it is not. In
addition, femoral cannulation is associated
with the potential for vascular complica-
tions (both venous and arterial), prevents
movement of the patient in the bed or at the
bedside, and limits flow by the relatively
small size of the cannulae. These views
were shared by other surgeons in a discus-
sion of acute heart failure with various
types of mechanical circulatory assist tech-
nologies.4
We congratulate Dr Khabbaz and his
team for their wonderful success and en-
courage others to think about mechanical
circulatory support when confronted with a
severe case of acute necrotizing eosino-
philic myocarditis. The use of ECLS is not
an unreasonable method to rapidly restore
circulatory stability. However, in the event
that ECLS is insufficient, then a more ad-
vanced form of mechanical circulatory sup-
port, such as a VAD, is appropriate.
Louis Samuels, MD, FACS
Surgical Director Cardiac Transplantation
Director Artificial Heart and VAD Program
Lankenau Hospital
Wynnewood, Pa
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Modern drainage techniques include
not only smaller drains for pain
reduction
To the Editor:
In a prospective, randomized, controlled trial,
Roberts and colleagues1 recently demon-
strated that the performance of small-bore
Blake drains (19F) (Ethicon Inc, Somerville,
NJ) is not inferior to that of standard Portex
drains (28F) (Portex, Inc, Hythe, Kent, UK)
after cardiac surgery. The study provides im-
portant evidence on the efficacy of modern
drainage techniques. However, we have
some comments.
The authors compared 199 patients un-
dergoing first-time cardiac procedures; 90
patients received Blake drains, and 109 pa-
tients received standard Portex drains. We
are not convinced that the influence of
complex valve procedures, which are more
frequent in the Blake group, is not statisti-
cally relevant. Furthermore, we believe that
a homogenous patient group might demon-
strate the advantage of silastic Blake drains
and allow extrapolation to other patient
groups.
Akowuah and colleagues2 demonstrated
less pain with Blake drains, but, as men-
tioned by Roberts and colleagues,1 with
only a small patient group (70 patients with
35 in each group). Therefore, it is a pity
that the authors did not assess pain with a
visual analog scale score, which is easy to
perform.
Finally, the authors somehow misquoted
our correspondence on the article by Barnard
and colleagues:3 We do not believe that “. . .
the only way to reduce patient discomfort is
to use smaller and softer drains.” In fact, we
stated that a modern drainage technique is a
fundamental part in pain reduction while re-
moving drains after thoracic and cardiac sur-
gery. Of course, analgesia, special removal
maneuvers, and so forth have value, as dem-
onstrated in various studies.4 In our unit, 10F
to 19F Blake drains are used in all patients
(1800 patients/year). Our observations are
consistent with the literature: The Blake drain
system is as effective as conventional drains
with no increased risk of retained blood in the
chest or tamponade and significantly less
pain for the patient. We therefore advocate
the use of Blake drains in patients undergoing
thoracic or cardiac surgery as well.
Helmut Mair, MD
Ingo Kaczmarek, MD
Sabine Daebritz, MD
Cardiac Surgery
University of Munich
Munich, Germany
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Reply to the Editor
We thank Dr Mair and colleagues for their
interest in our study1 and for their com-
ments to which we would like to reply.
First, we agree that homogenous patient
groups avoid confounding variables; the
influence of complex valve procedures is
one that was mentioned. However, we do
not agree that it was the heterogeneity of
the patient groups that prevented us from
demonstrating an advantage of the Blake
system (Ethicon Inc, Somerville, NJ). Our
study was powered on the statistical basis
of testing noninferiority, which allows sta-
tistical comparison with a predefined level
of difference between groups. Had the
study hypothesis been that Blake drains
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were superior to Portex drains (Portex, Inc,
Keene, NH), the power calculation of the
study would have been entirely different
and the patient number much higher. This
would have effectively made the study im-
possible to perform because of the logistic
difficulty of arranging postoperative echo-
cardiography in a defined time period after
drain removal.
Second, we agree that Akowuah and
colleagues2 clearly demonstrated less pain
associated with Blake drains when com-
pared with Portex drains. In fact, the dif-
ferences between the groups were dramat-
ic; thus, their conclusions about the benefit
of Blake drains on postoperative pain were
valid even with the small patient numbers.
Before initiating our study we performed
an assessment of pain scores between the
2 drain systems in patients with patient-
controlled analgesia postoperatively to avoid
the bias of unequal analgesic regimens. By
using a 0 to 100 visual analogue pain score,
we documented a similar baseline in 20
patients (21 25 Blake vs 34 26 Portex,
P  .28) but a lower drain removal score
(40  21 Blake vs 69  21 Portex, P 
.006) in favor of Blake drains. We believed
the benefit of Blake drains in terms of pain
reduction to be undoubted and performed
our study because it could be argued that
Akowuah and colleagues’ conclusions of
equivalence of drainage efficacy were
based on an underpowered sample.
Finally, we apologize if we misquoted
Mair and colleagues’ correspondence by
summarizing “the only way to reduce pa-
tient discomfort is to use smaller and softer
drains.” The exact quote in relation to Bar-
nard and colleagues’ article3 was “the au-
thors focus on analgesia for chest drain
removal. But in our opinion it is more
important to use modern drainage tech-
niques for pain reduction while removing
drains after thoracic and cardiac surgery.”
In this aspect we agree with Mair and col-
leagues that modern drainage techniques
are most important for pain reduction after
cardiothoracic surgery. We are pleased that
our randomized control trial data confirm
their clinical observations that Blake drains
are as effective as conventional drains, and
we also advocate their use.
Neil Roberts, MRCSa
Tom J. Spyt, FRCSb
Department of Cardiac Surgery
Northern General Hospitala
Sheffield, United Kingdom
Department of Cardiac Surgery
Glenfield Hospitalb
Leicester, United Kingdom
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Endovascular repair of postoperative
aortobronchopulmonary fistulas
To the Editor:
We read with great interest the brief com-
munication by Quintana and colleagues,1
and we congratulate their successful endo-
vascular treatment of an aortobronchial fis-
tula. Management of such fistulas is not
easy. Diagnosis is difficult due to the rarity
of this entity and because even modern
preoperative investigations sometimes fail
to directly visualize the fistula. Surgical
treatment represents a real challenge due to
coexistence of emergency conditions and
difficulties of redo operations. In a collec-
tive review of the literature (to our knowl-
edge the unique reporting specifically of
postoperative aortic fistulas into the air-
ways), which included all published cases
from 1947 to October 2002, one of us
(M.P.) found this complication in 76 patients,
for a total of 79 fistulas (3 patients were
affected by 2 fistulas).2 The review disclosed
that 50 fistulas involving the descending tho-
racic aorta were treated by heterogeneous
surgical procedures (primary, patch, or
subclavian flap repair, graft replacement,
homograft implant, extra-anatomic bypass
graft), with a mortality rate of 16% and
with most patients dying intraoperatively.
Instead, there were no deaths related to
procedure type, respectively, in 15 patients
treated by stent grafts, in 1 patient managed
by transcatheter embolization, and in 5 sur-
gically treated cases involving the ascend-
ing aorta. Although in selected patients en-
dovascular repair has been used as an
emergency or palliative alternative to treat
even primary fistulas due to atherosclerotic
aneurysms3 or pulmonary infectious dis-
ease,4 we believe that its best indication
lies in the late postoperative setting. De-
spite the potential infectious complications
of stent grafts, we believe that the endovas-
cular option to treat postoperative aorto-
bronchial and aortopulmonary fistulas rep-
resents the appropriate solution because it
avoids high morbidity and mortality rates
of urgent redo operations.
Marco Picichè, MD
Roland G. Demaria, MD, PhD
Bernard Albat, MD
Service de Chirurgie Cardio-Vasculaire
Chu Arnaud de Villeneuve
Montpellier, France
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